Labiotech.eu

News and Trends 19 Dec 2022

Ordaōs and Yatiri Bio to tackle AML

Ordaōs has announced a joint development agreement to create new therapeutics for two novel targets in acute myeloid leukemia (AML) with Yatiri Bio. Ordaōs is a biotechnology company designing novel mini-proteins to help drug hunters deliver life-saving treatments, and Yatiri Bio is a biotechnology company that has developed a proprietary platform that links patient proteomic […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Prenetics acquires ACT Genomics

Prenetics Global Limited is acquiring a majority stake in ACT Genomics Holdings Company Limited, an Asia based genomics company specializing in precision oncology with operations in Hong Kong, Taiwan, Japan, Singapore, Thailand and in the U.K. “With the addition of ACT’s technologies, capabilities and team, Prenetics will be well-positioned to accelerate the utilization of genetic […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Jacobio’s cancer treatment given breakthrough therapy designations by China CDE

Jacobio Pharma’s in-house KRAS G12C inhibitor JAB-21822 has been granted breakthrough therapy designations in China. The designations are for the second line and above treatment of advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRAS G12C mutation. The designations were granted by the Center for Drug Evaluation (CDE) of the National Medical Products […]

December 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Sanofi and Innate Pharma expand natural killer cell deal

Sanofi and Innate Pharma SA have expanded their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKET targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

LIfT BioSciences gets a double boost

LIfT BioSciences’ is receiving more investment, and has been accepted into Johnson & Johnson Innovation’s JLABS network. LIfT BioSciences’ lead investor, Starbloom Capital, provided further investment into the company to accelerate LIfT’s R&D plans and progress N-LIfT, the company’s first-to-market anti-cancer innate cell therapy, (neutrophil only leukocyte infusion therapy) into clinical development by Q1 2024, […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

SoftOx receives chronic wound study report

Norwegian company SoftOx Solutions AS says it has received the final report and analysis of its phase 1 study evaluating the safety and tolerability of SoftOx Biofilm Eradicator (SBE-01). SBE-01 is SoftOx’s antimicrobial solution for the treatment of chronic wounds. The study is a first-in-human investigation of the safety, tolerability, and antimicrobial efficacy of single […]

December 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Nykode Therapeutics and Richter-Helm BioLogics announce partnership

Nykode Therapeutics ASA has entered into a strategic manufacturing partnership with Richter-Helm BioLogics GmbH & Co KG to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio. “We are excited about the strategic manufacturing partnership with Richter-Helm BioLogics. As a leading manufacturer of DNA vaccines, they will provide the long-term expertise and capacity […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

Swedish research center expanding to take on antimicrobial resistance

Research on antibiotic resistance will get a boost when the Center for Antibiotic Resistance Research (CARe) in Gothenburg, Sweden, expands. Bacterial resistance to antibiotics is one of the most serious global health threats. More than a million people die annually as a direct result of infections caused by resistant bacteria. Lack of effective antibiotics jeopardizes […]

December 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

Astellas gastric cancer drug meets phase 3 primary endpoint

Astellas Pharma Inc. has announced positive topline results from the phase 3 GLOW clinical trial evaluating the efficacy and safety of zolbetuximab in combination with CAPOX (a combination chemotherapy regimen that includes capecitabine and oxaliplatin). Zolbetuximab is an investigational first-in-class claudin-18.2 (CLDN18.2) targeted monoclonal antibody, for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally […]

December 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

Providence Therapeutics’ mRNA rabies vaccine hits milestone

Providence Therapeutics Holdings Inc. says its new mRNA vaccine program for rabies post-exposure prophylaxis has achieved a preclinical proof-of-concept milestone. The candidate was developed in partnership with Everest Medicines utilizing Providence’s clinically validated mRNA technology platform. “We are pleased to demonstrate that Providence’s mRNA technology supports development of additional products that fight a number of […]

December 16, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

Beyond Biotech podcast 26: CellCentric, MicrofluidX, Potter Clarkson

This week, we have three guests. We have conversations with Antoine Espinet, CEO of MicrofluidX; Will West, CEO of CellCentric; and Sara Holland, patent attorney at Potter Clarkson. MicrofluidX raises £3.3M to develop advanced therapy manufacturing platform MicrofluidX (MFX), a U.K. based provider of next-generation bioreactors for cell research and manufacturing, today announces £3.3 million […]

December 16, 2022

News and Trends 16 Dec 2022

CSL closer to gene therapy treatments for hemophilia B patients in Europe

CSL says the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization (CMA) of etranacogene dezaparvovec. Etranacogene dezaparvovec is a one-time gene therapy for the treatment of appropriate adults with hemophilia B that reduces the rate of annual bleeds with a single infusion. […]

December 16, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Ordaōs and Yatiri Bio to tackle AML

Prenetics acquires ACT Genomics

Jacobio’s cancer treatment given breakthrough therapy designations by China CDE

Sanofi and Innate Pharma expand natural killer cell deal

LIfT BioSciences gets a double boost

SoftOx receives chronic wound study report

Nykode Therapeutics and Richter-Helm BioLogics announce partnership

Swedish research center expanding to take on antimicrobial resistance

Astellas gastric cancer drug meets phase 3 primary endpoint

Providence Therapeutics’ mRNA rabies vaccine hits milestone

Beyond Biotech podcast 26: CellCentric, MicrofluidX, Potter Clarkson

CSL closer to gene therapy treatments for hemophilia B patients in Europe

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!